Allergan Announces Completion of UBR-MD-04 & 3110-105-002 Study for Treatment of Migrane

 Allergan Announces Completion of UBR-MD-04 & 3110-105-002 Study for Treatment of Migrane

Allergan Announces Completion of UBR-MD-04 & 3110-105-002 Study for Treatment of Migrane

Shots:

  • The two pivotal study conducted for assessing ubrogepant (50/100) vs usual care & ubrogepant (100) vs PBO for 1year & 8 wks. respectively to treat migrane in adults, evaluating its safety, tolerability & hepatic safety
  • UBR-MD-04 (N=1,254) & 3110-105-002(N=516) study results: 21,454 migraine attacks were treated with 31,968 doses of ubrogepant with mean number 25.5 (50 mg) and 27.2 (100 mg) @52wks.; no signal of drug-induced liver injury or a hepatic safety concern was observed
  • Allegan plans to file NDA submission with efficacy and safety results from ACHIEVE I & II (UBR-MD-01 & UBR-MD-02), UBR-MD-04 & 3110-105-002 in H1’19

Click here to read full press release/ article | Ref: Novartis | Image: Endpts

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post